Total Payments
$499,445
2024 Payments
$135,900
Companies
32
Transactions
668
Medicare Patients
1,520
Medicare Billing
$81,306
Payment Breakdown by Category
Consulting$240,290 (48.1%)
Other$157,493 (31.5%)
Travel$45,682 (9.1%)
Research$36,765 (7.4%)
Food & Beverage$19,082 (3.8%)
Education$132.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $240,290 | 74 | 48.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $154,406 | 65 | 30.9% |
| Travel and Lodging | $45,682 | 132 | 9.1% |
| Unspecified | $36,765 | 29 | 7.4% |
| Food and Beverage | $19,082 | 361 | 3.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,000 | 1 | 0.6% |
| Education | $132.56 | 4 | 0.0% |
| Grant | $87.00 | 2 | 0.0% |
Payments by Type
General
$462,679
639 transactions
Research
$36,765
29 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $95,068 | 103 | $0 (2024) |
| ABBVIE INC. | $87,647 | 125 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $49,331 | 36 | $0 (2024) |
| Janssen Biotech, Inc. | $44,746 | 74 | $0 (2024) |
| Eli Lilly and Company | $43,746 | 39 | $0 (2022) |
| PFIZER INC. | $41,036 | 17 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $29,592 | 47 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $28,879 | 51 | $0 (2024) |
| GENZYME CORPORATION | $16,241 | 13 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $14,499 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $135,900 | 122 | ABBVIE INC. ($34,521) |
| 2023 | $137,407 | 210 | Arcutis Biotherapeutics, Inc. ($29,511) |
| 2022 | $58,164 | 105 | E.R. Squibb & Sons, L.L.C. ($29,378) |
| 2021 | $23,804 | 37 | AbbVie Inc. ($9,482) |
| 2020 | $21,004 | 14 | PFIZER INC. ($11,200) |
| 2019 | $60,211 | 89 | Eli Lilly and Company ($19,815) |
| 2018 | $37,586 | 43 | Eli Lilly and Company ($17,138) |
| 2017 | $25,370 | 48 | Novartis Pharmaceuticals Corporation ($8,773) |
All Payment Transactions
668 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $341.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $298.71 | General |
| Category: IMMUNOLOGY | ||||||
| 11/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $51.11 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $37.04 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $308.26 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $249.66 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $202.70 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $118.65 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $7.32 | General |
| 10/24/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $127.11 | General |
| Category: DERMATOLOGY | ||||||
| 10/24/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $54.79 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.59 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/23/2024 | Journey Medical Corporation | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| Category: Immunology | ||||||
| 10/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $69.88 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $13.40 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $292.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.81 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $15,509 | 5 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $11,437 | 1 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $3,549 | 2 |
| A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | AbbVie Inc. | $1,750 | 9 |
| CC-10004-PSOR-008 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis | Celgene Corporation | $1,524 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $1,509 | 10 |
| CC-10004-PSOR-009 | Celgene Corporation | $1,488 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 373 | 492 | $107,985 | $22,257 |
| 2022 | 7 | 363 | 445 | $80,742 | $19,264 |
| 2021 | 8 | 418 | 515 | $88,183 | $21,793 |
| 2020 | 10 | 366 | 463 | $82,610 | $17,992 |
Total Patients
1,520
Total Services
1,915
Medicare Billing
$81,306
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 80 | 93 | $11,904 | $4,234 | 35.6% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 31 | 31 | $23,126 | $3,518 | 15.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 46 | 53 | $9,964 | $3,243 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 40 | $7,758 | $2,795 | 36.0% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 11 | 11 | $6,941 | $1,635 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 29 | 30 | $3,945 | $1,534 | 38.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 33 | 40 | $7,840 | $1,425 | 18.2% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 15 | 19 | $10,469 | $1,302 | 12.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 19 | 22 | $3,058 | $944.32 | 30.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 32 | 35 | $5,775 | $717.50 | 12.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 12 | 13 | $2,548 | $419.08 | 16.4% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2023 | 11 | 13 | $2,145 | $350.40 | 16.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 23 | 92 | $12,512 | $140.36 | 1.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 100 | 117 | $14,976 | $5,181 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 62 | $11,656 | $4,075 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 31 | 37 | $7,330 | $2,561 | 34.9% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 19 | 19 | $14,174 | $1,969 | 13.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 36 | 39 | $5,076 | $1,703 | 33.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 42 | 49 | $9,604 | $1,661 | 17.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 27 | 29 | $4,031 | $1,114 | 27.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 40 | 43 | $7,095 | $920.29 | 13.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 20 | 50 | $6,800 | $79.86 | 1.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 103 | 116 | $14,848 | $5,373 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 66 | $12,408 | $4,494 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 53 | $10,372 | $3,699 | 35.7% |
About Laura Ferris
Laura Ferris is a Specialist healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043283229.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Laura Ferris has received a total of $499,445 in payments from pharmaceutical and medical device companies, with $135,900 received in 2024. These payments were reported across 668 transactions from 32 companies. The most common payment nature is "Consulting Fee" ($240,290).
As a Medicare-enrolled provider, Ferris has provided services to 1,520 Medicare beneficiaries, totaling 1,915 services with total Medicare billing of $81,306. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Pittsburgh, PA
- Active Since 02/09/2006
- Last Updated 03/25/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1043283229
Products in Payments
- SKYRIZI (Biological) $49,565
- SPEVIGO (Drug) $42,947
- DUPIXENT (Biological) $37,592
- Sotyktu (Drug) $28,608
- TREMFYA (Drug) $26,066
- TALTZ (Drug) $17,482
- LITFULO (Drug) $15,500
- EUCRISA (Drug) $13,233
- Tremfya (Drug) $12,005
- COSENTYX (Biological) $8,838
- OPDIVO (Biological) $8,143
- Otezla (Drug) $7,225
- Humira (Biological) $6,950
- COSENTYX (Drug) $4,979
- Cimzia (Drug) $4,836
- ILUMYA (Biological) $4,424
- VTAMA (Drug) $3,237
- LIBTAYO (Biological) $3,223
- SILIQ (Drug) $2,898
- RINVOQ (Biological) $2,137
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Pittsburgh
Dr. Lawrence Crossett, Md, MD
Specialist — Payments: $5.3M
Specialist $5.3M
Dr. James Bradley, Md, MD
Specialist — Payments: $5.0M
Specialist $5.0M
Darrell Triulzi
Specialist — Payments: $3.3M
Specialist $3.3M
Dr. Mark Yazer, Md, MD
Specialist — Payments: $2.4M
Specialist $2.4M
Lirong Qu
Specialist — Payments: $2.4M
Specialist $2.4M
Dr. Miguel Regueiro, Md, MD
Specialist — Payments: $1.4M
Specialist $1.4M